News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
HUTCHMED Last Leaps ~5%, While INNOVENT BIO Falters; Application for Combination Therapy for RCC Accepted
HUTCHMED (00013.HK) and INNOVENT BIO (01801.HK) jointly announced that the New Drug Application for the combination of fruquintinib and sintilimab for the treatment of patients wit...
Reset
Send
The window will close in 5 seconds
HUTCHMED Last Leaps ~5%, While INNOVENT BIO Falters; Application for Combination Therapy for RCC Accepted
Close
Recommend
11
Positive
20
Negative
9
 
SHORT SELL
 
STOCK INFO

HUTCHMED (00013.HK)  +0.150 (+0.626%)    Short selling $15.69M; Ratio 8.418%   and INNOVENT BIO (01801.HK)  +0.850 (+1.176%)    Short selling $121.31M; Ratio 6.982%   jointly announced that the New Drug Application for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma (RCC) who have failed prior treatment with one tyrosine kinase inhibitor has been accepted for review by the China National Medical Products Administration.

HUTCHMED opened 2.53% higher this morning and once climbed to a peak of HKD25.1. It last traded at HKD24.85, up 4.85%, on a volume of 2.623 million shares and a turnover of HKD64.9228 million.

Related NewsG Sachs Elevates INNOVENT BIO (01801.HK) TP to $74.95, Rating Buy
Hyped up yesterday, INNOVENT BIO opened flat this morning and once sank to a bottom of HKD71.8. It was last at HKD72.1, down 2.9%, on a volume of 4.4799 million shares and a turnover of HKD326 million.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-06 16:25.)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.